An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Ifidancitinib (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Aclaris Therapeutics
- 25 Nov 2020 Status changed from discontinued to completed.
- 08 Aug 2019 Status changed from active, no longer recruiting to discontinued based on the interim analysis results.
- 08 Aug 2019 Interim results presented in the Aclaris Therapeutics financial media release.